Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
X-linked adrenomyeloneuropathy (AMN) is an inherited neurometabolic disorder caused by malfunction of the ABCD1 gene, characterized by slowly progressing spastic paraplegia affecting corticospinal tracts, and adrenal insufficiency. AMN is the most common phenotypic manifestation of adrenoleukodystrophy (X-ALD). In some cases, an inflammatory cerebral demyelination occurs associated to poor prognosis in cerebral AMN (cAMN). Though ABCD1 codes for a peroxisomal transporter of very long-chain fatty acids, the molecular mechanisms that govern disease onset and progression, or its transformation to a cerebral, inflammatory demyelinating form, remain largely unknown. Here we used an integrated -omics approach to identify novel biomarkers and altered network dynamic characteristic of, and possibly driving, the disease. We combined an untargeted metabolome assay of plasma and peripheral blood mononuclear cells (PBMC) of AMN patients, which used liquid chromatography coupled to quadrupole-time-of-flight mass spectrometry (LC-Q-TOF), with a functional genomics analysis of spinal cords of Abcd1(-) mouse. The results uncovered altered nodes in lipid-driven proinflammatory cascades, such as glycosphingolipid and glycerophospholipid synthesis, governed by the β-1,4-galactosyltransferase (B4GALT6), the phospholipase 2γ (PLA2G4C) and the choline/ethanolamine phosphotransferase (CEPT1) enzymes. Confirmatory investigations revealed a non-classic, inflammatory profile, consisting on the one hand of raised plasma levels of several eicosanoids derived from arachidonic acid through PLA2G4C activity, together with also the proinflammatory cytokines IL6, IL8, MCP-1 and tumor necrosis factor-α. In contrast, we detected a more protective, Th2-shifted response in PBMC. Thus, our findings illustrate a previously unreported connection between ABCD1 dysfunction, glyco- and glycerolipid-driven inflammatory signaling and a fine-tuned inflammatory response underlying a disease considered non-inflammatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Very recently, a gene therapy approach correcting CD34 cells with the ABCD1 cDNA, using a lentiviral vector, has proved to be successful and, being less invasive, is a good alternative to transplantation (10,11).”
BackgroundA review of the volatiles from the healthy human body
de Lacy Costello, B., Amann, A., Al-Kateb, H., Flynn, C., Filipiak, W., Khalid, T., Osborne, D., & Ratcliffe, N. M. (2014) · Journal of Breath Research · doi:10.1088/1752-7155/8/1/014001 · Cited by 1,042 · cited 1×
“Several other methyl-derived fatty acids are part of the volatiles present in organic compartments (52).”
BackgroundBiochemistry of mammalian peroxisomes revisited
Wanders, R. J. A., & Waterham, H. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133329 · Cited by 995 · cited 1×
“Thus, decreased availability of substrates for peroxisomal β-oxidation, owing to deficient transport of the very long-chain fatty acids substrate by ABCD1 (6), can contribute to decreased levels of n-hexanoic acid, one of the final products of very long-chain fatty acids β-oxidation, which is then degraded in mitochon…”
BackgroundJAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00128-6 · Cited by 555
Peripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547
IL-9 as a mediator of Th17-driven inflammatory disease
Nowak, E. C., Weaver, C. T., Turner, H., Begum-Haque, S., Becher, B., Schreiner, B., Coyle, A. J., Kasper, L. H., & Noelle, R. J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090246 · Cited by 393
Aubourg, P., Blanche, S., Jambaqué, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.-O., Debré, M., Chaussain, J.-L., Griscelli, C., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222607 · Cited by 366 · cited 1×
“For cALD patients, the only treatment to date is allogeneic bone marrow transplantation, which is associated with a high morbidity and mortality and is available only to nearly asymptomatic X-ALD children (9).”
BackgroundVillalta, S. A., Rinaldi, C., Deng, B., Liu, G., Fedor, B., & Tidball, J. G. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq523 · Cited by 299 · cited 1×
“For instance, it has been reported that IL10, initially described as a Th2 cytokine able to inhibit IFNγ production by Th1 cells (89), is also produced by monocytes, dendritic cells and other lymphocyte subsets in response to inflammatory in-”
BackgroundA mouse model for X-linked adrenoleukodystrophy
Lu, J.-F., Lawler, A. M., Watkins, P. A., Powers, J. M., Moser, A. B., Moser, H. W., & Smith, K. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9366 · Cited by 293 · cited 1×
“The generation and genotyping of Abcd1 mice have been previously described (23,96).”
MethodPOWERS, J. M., LIU, Y., MOSER, A. B., & MOSER, H. W. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00007 · Cited by 265
Oncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242 · cited 1×
“In contrast, forAMNpatients, there isno satisfactory treatment to date (12,13).”
BackgroundThe human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl–CoA esters
van Roermund, C. W. T., Visser, W. F., IJlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H. R., & Wanders, R. J. A. (2008) · The FASEB Journal · doi:10.1096/fj.08-110866 · Cited by 233
Pujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214 · cited 2×
“The identification of targets in these pathways, such as PGC-1α, Sirt1, or mTOR, which can be targeted with drugs, has led to successful preclinical tests (17,19–22) in the Abcd1 mouse model (17,19–22) [a model for AMN (23)], which warrant clinical trials.”
BackgroundMethodSelf-citationEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214 · cited 2×
“6A–C), very early in life at 3 months of age, when first signs of lipo-oxidative damage (MDAL) appear (58).”
BackgroundSelf-citationAdrenomyeloneuropathy: A Neuropathologic Review Featuring Its Noninflammatory Myelopathy
Powers, J. M., DeCiero, D. P., Ito, M., Moser, A. B., & Moser, H. W. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.2.89 · Cited by 204
Ho, J. K., Moser, H., Kishimoto, Y., & Hamilton, J. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118182 · Cited by 199 · cited 1×
“In particular, C26:0 has been predicted to exert disruptive effects onmembrane structure and functions by interfering with the lateral chains of phospholipids (67).”
BackgroundMetabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases
Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195
Self-citationWhitcomb, R. W., Linehan, W. M., & Knazek, R. A. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113292 · Cited by 168 · cited 1×
“It is well known that the length of the glycerophospholipid acyl chain and the degree of saturation are important determinants of physical properties such as membrane microviscosity and have been found altered in X-ALD erythrocytes and adrenocortical cells (65,66).”
BackgroundPathomechanisms underlying X-adrenoleukodystrophy: A three-hit hypothesis
Singh, I., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00392.x · Cited by 148 · cited 1×
“Therefore, additional pathogenic factors critically shaping the clinicalmanifestation of X-ALD /X-AMN ought to exist (24).”
BackgroundSelf-citationWiesinger, C., Kunze, M., Regelsberger, G., Forss-Petter, S., & Berger, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445445 · Cited by 145 · cited 11×
“Although the entire clinical spectrum of X-ALD is initiated by mutations in a single gene, theABCD1, the pathomechanisms for demyelination, the inflammatory process, the axonal degeneration and the adrenal insufficiency clearly differ.”
BackgroundInfluentialGeneral aspects and neuropathology of X-linked adrenoleukodystrophy
Ferrer, I., Aubourg, P., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00390.x · Cited by 139 · cited 1×
“Each sample was run in duplicate, and the mean value of the duplicates was used to calculate the mRNA expression using the comparative (2) method, according to”
MethodSelf-citationLópez-Erauskin, J., Galino, J., Ruiz, M., Cuezva, J. M., Fabregat, I., Cacabelos, D., Boada, J., Martínez, J., Ferrer, I., Pamplona, R., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt186 · Cited by 125 · cited 3×
“We therefore posit that a derangement in the bioactive glycerophospholipid composition may be the initial driver of an inflammatory signaling cascade, to which mitochondria ROS production may decisively contribute and possibly exacerbate (16,69).”
BackgroundSelf-citationA key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis
Fourcade, S., Ruiz, M., Camps, C., Schlüter, A., Houten, S. M., Mooyer, P. A. W., Pàmpols, T., Dacremont, G., Wanders, R. J. A., Giròs, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90736.2008 · Cited by 104
Self-citationMcGuinness, M. C., Powers, J. M., Bias, W. B., Schmeckpeper, B. J., Segal, A. H., Gowda, V. C., Wesselingh, S. L., Berger, J., Griffin, D. E., & Smith, K. D. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00020-9 · Cited by 89
Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy
Schlüter, A., Espinosa, L., Fourcade, S., Galino, J., López, E., Ilieva, E., Morató, L., Asheuer, M., Cook, T., McLaren, A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr536 · Cited by 72
Self-citationKruska, N., Schönfeld, P., Pujol, A., & Reiser, G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.005 · Cited by 56
Self-citationFourcade, S., López-Erauskin, J., Ruiz, M., Ferrer, I., & Pujol, A. (2014) · Biochimie · doi:10.1016/j.biochi.2013.09.012 · Cited by 55
Self-citationXie, Y. (., Lee, W., Cai, C., Gambin, T., Nõupuu, K., Sujirakul, T., Ayuso, C., Jhangiani, S., Muzny, D., Boerwinkle, E., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu291 · Cited by 40
Cited by
The Axon-Myelin Unit in Development and Degenerative Disease
Stassart, R. M., Möbius, W., Nave, K.-A., & Edgar, J. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00467 · Cited by 246
“inflammatory mediators has been proposed (Kassmann and Nave, 2008; Ruiz et al., 2015) for both AMN and the allelic disorder X-linked adrenoleukodystrophy”
BackgroundDisease progression in women with X-linked adrenoleukodystrophy is slow
Huffnagel, I. C., Dijkgraaf, M. G. W., Janssens, G. E., van Weeghel, M., van Geel, B. M., Poll-The, B. T., Kemp, S., & Engelen, M. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1008-6 · Cited by 100
“Using a comparable lipidomics approach Ruiz et al. (2015) reported similar differences in abundancy of lipids between 13 men with ALD and 13 controls [33].”
BackgroundResultImpaired plasticity of macrophages in X-linked adrenoleukodystrophy
Weinhofer, I., Zierfuss, B., Hametner, S., Wagner, M., Popitsch, N., Machacek, C., Bartolini, B., Zlabinger, G., Ohradanova-Repic, A., Stockinger, H., et al. (2018) · Brain · doi:10.1093/brain/awy127 · Cited by 72
“ipheral blood mononuclear cells isolated from patients with AMN (Ruiz et al., 2015).”
BackgroundZhang, L., Niu, M., Wei, A.-W., Tang, J.-F., Tu, C., Bai, Z.-F., Zou, Z.-S., Xiao, X.-H., Liu, Y.-P., & Wang, J.-B. (2020) · Archives of Toxicology · doi:10.1007/s00204-019-02595-3 · Cited by 49
Strachan, L. R., Stevenson, T. J., Freshner, B., Keefe, M. D., Miranda Bowles, D., & Bonkowsky, J. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx249 · Cited by 46
Metadata
- Authors
- Ruiz, M., Jové, M., Schlüter, A., Casasnovas, C., Villarroya, F., Guilera, C., Ortega, F. J., Naudí, A., Pamplona, R., Gimeno, R., Fourcade, S., Portero-Otín, M., & Pujol, A.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-14
- Volume
- 24
- Issue
- 24
- Pages
- ddv375
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W1912743953
- Cited by
- 45
- References
- 31
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.